Technical Analysis for RGLS - Regulus Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
1.11 | 2.78% | 0.03 |
RGLS closed up 2.78 percent on Friday, January 18, 2019, on 1.44 times normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical RGLS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 18 | Crossed Above 20 DMA | Bullish | 0.00% |
| Jan 18 | Hammer Candlestick | Bullish | 0.00% |
| Jan 18 | Doji - Bullish? | Reversal | 0.00% |
| Jan 18 | Wide Bands | Range Expansion | 0.00% |
| Jan 17 | Fell Below 20 DMA | Bearish | 2.78% |
| Jan 17 | Wide Bands | Range Expansion | 2.78% |
| Jan 16 | Wide Bands | Range Expansion | -2.63% |
| Jan 15 | Pocket Pivot | Bullish Swing Setup | -3.48% |
| Jan 15 | Volume Surge | Other | -3.48% |
| Jan 15 | Wide Bands | Range Expansion | -3.48% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-06
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more RGLS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 16.8 |
| 52 Week Low | 0.8 |
| Average Volume | 303,651 |
| 200-Day Moving Average | 4.1609 |
| 50-Day Moving Average | 1.3345 |
| 20-Day Moving Average | 1.0973 |
| 10-Day Moving Average | 1.159 |
| Average True Range | 0.1553 |
| ADX | 11.02 |
| +DI | 19.4669 |
| -DI | 23.7531 |
| Chandelier Exit (Long, 3 ATRs ) | 0.9041 |
| Chandelier Exit (Short, 3 ATRs ) | 1.2659 |
| Upper Bollinger Band | 1.3447 |
| Lower Bollinger Band | 0.8499 |
| Percent B (%b) | 0.53 |
| BandWidth | 45.0925 |
| MACD Line | -0.0609 |
| MACD Signal Line | -0.0761 |
| MACD Histogram | 0.0152 |
| Fundamentals | Value |
|---|---|
| Market Cap | 115.2 Million |
| Num Shares | 104 Million |
| EPS | -1.53 |
| Price-to-Earnings (P/E) Ratio | -0.73 |
| Price-to-Sales | 450.54 |
| Price-to-Book | 2.98 |
| PEG Ratio | -0.03 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.26 | ||||
| Resistance 3 (R3) | 1.25 | 1.18 | 1.24 | ||
| Resistance 2 (R2) | 1.18 | 1.15 | 1.19 | 1.23 | |
| Resistance 1 (R1) | 1.15 | 1.12 | 1.17 | 1.16 | 1.22 |
| Pivot Point | 1.08 | 1.08 | 1.09 | 1.09 | 1.08 |
| Support 1 (S1) | 1.05 | 1.05 | 1.07 | 1.06 | 1.00 |
| Support 2 (S2) | 0.98 | 1.02 | 0.99 | 0.99 | |
| Support 3 (S3) | 0.95 | 0.98 | 0.99 | ||
| Support 4 (S4) | 0.96 |
